TY - JOUR
T1 - Designing antimicrobial peptides
T2 - Form follows function
AU - Fjell, Christopher D.
AU - Hiss, Jan A.
AU - Hancock, Robert E.W.
AU - Schneider, Gisbert
N1 - Funding Information:
R.E.W.H. holds a Canada Research Chair position, and his current peptide research is supported by the Canadian Institutes of Health Research (CIHR). C.D.F. holds a CIHR postdoctoral fellowship. This study was partially supported by grants to J.A.H. and G.S. from the Swiss National Science Foundation (Grant number: 205321-134783) and the German Research Foundation (Deutsche Forschungsgemeinschaft) (Grant number: FOR1406TP4).
PY - 2012/1
Y1 - 2012/1
N2 - Multidrug-resistant bacteria are a severe threat to public health. Conventional antibiotics are becoming increasingly ineffective as a result of resistance, and it is imperative to find new antibacterial strategies. Natural antimicrobials, known as host defence peptides or antimicrobial peptides, defend host organisms against microbes but most have modest direct antibiotic activity. Enhanced variants have been developed using straightforward design and optimization strategies and are being tested clinically. Here, we describe advanced computer-assisted design strategies that address the difficult problem of relating primary sequence to peptide structure, and are delivering more potent, cost-effective, broad-spectrum peptides as potential next-generation antibiotics.
AB - Multidrug-resistant bacteria are a severe threat to public health. Conventional antibiotics are becoming increasingly ineffective as a result of resistance, and it is imperative to find new antibacterial strategies. Natural antimicrobials, known as host defence peptides or antimicrobial peptides, defend host organisms against microbes but most have modest direct antibiotic activity. Enhanced variants have been developed using straightforward design and optimization strategies and are being tested clinically. Here, we describe advanced computer-assisted design strategies that address the difficult problem of relating primary sequence to peptide structure, and are delivering more potent, cost-effective, broad-spectrum peptides as potential next-generation antibiotics.
UR - http://www.scopus.com/inward/record.url?scp=84857411069&partnerID=8YFLogxK
U2 - 10.1038/nrd3591
DO - 10.1038/nrd3591
M3 - Review article
C2 - 22173434
AN - SCOPUS:84857411069
SN - 1474-1776
VL - 11
SP - 37
EP - 51
JO - Nature Reviews Drug Discovery
JF - Nature Reviews Drug Discovery
IS - 1
ER -